Skip to main content

Table 1 Baseline characteristics of study cohort (n = 132)

From: Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Characteristic Entire cohort (n = 132) CC-CCD, mg/m2 P valuea
< 160 (n = 52, %) ≥ 160 (n = 80, %)
Sex 0.354
 Male 92 (69.7) 39 (75.0) 53 (66.2)  
 Female 40 (30.3) 13 (25.0) 27 (33.8)  
Age, years 0.494
 ≤ 15 69 (52.3) 25 (48.1) 44 (55.0)  
 < 15 63 (47.7) 27 (51.9) 36 (45.0)  
Smoking history 0.170
 No 123 (93.2) 46 (88.5) 77 (96.2)  
 Yes 9 (6.8) 6 (11.5) 3 (3.8)  
BMI, m2 0.310
 ≤ 1.45 64 (48.5) 22 (42.3) 42 (52.5)  
 > 1.45 68 (51.5) 30 (57.7) 38 (47.5)  
EBV DNA, copy/mL 0.293
 < 4000 52 (39.4) 17 (32.7) 35 (43.7)  
 ≥ 4000 80 (60.6) 35 (67.3) 45 (56.3)  
T stageb 0.281
 T1 1 (0.8) 1 (1.9) 0 (0)  
 T2 4 (3.0) 1 (1.9) 3 (3.8)  
 T3 59 (44.7) 27 (51.9) 32 (40.0)  
 T4 68 (51.5) 23 (44.2) 45 (56.3)  
N stageb 0.165
 N0 1 (0.8) 1 (1.9) 0 (0)  
 N1 18 (13.6) 8 (15.4) 10 (12.5)  
 N2 65 (49.2) 29 (55.8) 36 (45.0)  
 N3 48 (36.4) 14 (26.9) 34 (42.5)  
Overall stageb 0.114
 III 36 (27.3) 19 (36.5) 17 (21.3)  
 IVA 48 (36.4) 19 (36.5) 29 (36.2)  
 IVB 48 (36.4) 14 (26.9) 34 (42.5)  
NAC cycles 0.062
 2 60 (45.5) 30 (57.7) 30 (37.5)  
 3 66 (50.0) 21 (40.4) 45 (56.3)  
 4 6 (4.5) 1 (1.9) 5 (6.2)  
NAC regimens < 0.001
 TPF 73 (55.3) 18 (34.6) 55 (68.8)  
 TP 20 (15.2) 13 (25.0) 7 (8.8)  
 PF 35 (26.5) 21 (40.4) 14 (17.5)  
 GP 4 (3.0) 0 (0.00) 4 (5.0)  
Adjuvant chemotherapy 0.575
 No 129 (97.7) 50 (96.1) 79 (98.7)  
 Yes 3 (2.3) 2 (3.9) 1 (1.3)  
NAC-CCD, mg/m2 0.112
 < 180 62 (47.0) 29 (55.8) 33 (41.3)  
 ≥ 180 70 (53.0) 23 (44.2) 47 (58.7)  
Radiation dose, cGy 0.386
 < 6800 64 (49.6) 22 (44.0) 42 (53.2)  
 ≥ 6800 65 (50.4) 28 (56.0) 37 (46.8)  
  1. CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, BMI body mass index, EBV Epstein–Barr virus, NAC neoadjuvant chemotherapy, TPF cisplatin with 5-fluorouracil and toxoids, TP cisplatin with toxoids, PF cisplatin with 5-fluorouracil, GP cisplatin with gemcitabine, NAC-CCD cumulative cisplatin dose during neoadjuvant chemotherapy
  2. aP values were calculated using the chi-square test or Fisher exact test if indicated
  3. bAccording to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system